We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Biomarkers Distinguish Latent from Active TB

By LabMedica International staff writers
Posted on 02 Aug 2010
Print article
Multicytokine profiles of patients can determine if they have active or dormant tuberculosis (TB).

A pattern of two cytokines was reasonably good at differentiating between persons sick with TB and persons infected but not ill. In addition, a third cytokine looks promising in distinguishing between uninfected persons and infected individuals.

Cytokines are proteins that are secreted by cells and regulate the behavior of other cells by binding to receptors on their surfaces. This binding triggers a variety of responses, depending on the nature of the cytokine and the target cell.

In a study, carried out at Duke University Medical Center (Duke University; Durham, NC, USA), whole blood samples were collected from 71 people belonging to one of three groups: those with active TB, those with latent TB infection, and those who were not infected with Mycobacterium tuberculosis. The blood samples were exposed overnight with mitogen (positive control), saline (negative control), and a mixture of three tubercles bacillus antigens that stimulated an immune response. Scientists then measured the levels of 25 specific cytokines, to determine the presence of a pattern that could allow them to differentiate among the three groups.

Four cytokines had significantly greater response to stimulation in TB-infected persons (active or latent) than in uninfected persons: interferon gamma, IP-10, MCP-1, and IL-15. Of these, two cytokines had significantly greater responses to stimulation among persons with active TB than persons with latent TB: MCP-1 where the median response was 30,000 pg/mL in active TB and 11,100 pg/mL in latent TB. For IL-15 the median response in active TB was 152 pg/mL and 35 pg/mL in latent TB. A combination of MCP-1 and IL-15 at cutoffs of greater than 25,000 pg/mL and 80 pg/mL respectively, correctly categorized 10 of 12 active TB infections and 28 of 32 latent TB infections.

The resurgence of tuberculosis has resulted in the declaration of a global health emergency by the World Health Organization (WHO, Geneva, Switzerland, www.who.int). Every year, nearly half a million new cases of multidrug-resistant tuberculosis (MDR-TB) are estimated to occur worldwide. Jason Stout, M.D., M.H.S., assistant professor at Duke University, said, "Generally a culture is required to tell the difference between latent infection and active tuberculosis, but a culture usually requires weeks to deliver a result. A rapid test that could tell the difference between latent and active tuberculosis would be a major step forward.” The findings were reported at the American Thoracic Society International Conference held in New Orleans in May 2010.

Related Links:

Duke University Medical Center
WHO


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
25-OH-VD Reagent Kit
New
Respiratory QC Panel
Assayed Respiratory Control Panel

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.